In parallel, A3 AR agonists have demonstrated therapeutic potential in various immune-mediated and proliferative disorders, such as plaque psoriasis, hepatocellular carcinoma (HCC), and non-alcoholic steatohepatitis (NASH). This evidence concerns the gene ADORA3 and metabolic dysfunction-associated steatohepatitis.